Published in Ann N Y Acad Sci on October 29, 1993
The neurobiology of stress and gastrointestinal disease. Gut (2000) 2.09
Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci U S A (1997) 2.04
Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg (1998) 2.00
Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut (2004) 1.58
Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. Ann Surg (2003) 1.42
Gastric Dysmotility in Critically Ill Children: Pathophysiology, Diagnosis, and Management. Pediatr Crit Care Med (2015) 1.39
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol (2009) 1.24
Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol (2007) 1.24
Postoperative ileus: impact of pharmacological treatment, laparoscopic surgery and enhanced recovery pathways. World J Gastroenterol (2010) 1.15
Colonic postoperative inflammatory ileus in the rat. Ann Surg (2002) 1.08
Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice. J Neurosci (2012) 1.07
Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol (2012) 1.03
Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol (2014) 0.96
Norepinephrine mediates the transcriptional effects of heterotypic chronic stress on colonic motor function. Am J Physiol Gastrointest Liver Physiol (2009) 0.96
Updates on treatment of irritable bowel syndrome. World J Gastroenterol (2008) 0.94
Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis (2009) 0.93
Organization and Integration of the Endocrine System. Sleep Med Clin (2007) 0.90
Role of anger in antral motor activity in irritable bowel syndrome. Dig Dis Sci (2000) 0.90
Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol (2002) 0.88
IBS--review and what's new. MedGenMed (2006) 0.87
Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr Physiol (2014) 0.86
Preventing prolonged post-operative ileus in gastric cancer patients undergoing gastrectomy and intra-peritoneal chemotherapy. World J Gastroenterol (2005) 0.86
Can modulating corticotropin releasing hormone receptors alter visceral sensitivity? Gut (2006) 0.84
Ileus and the macrophage. Ann Surg (2003) 0.81
Endogenous Opioids: The Downside of Opposing Stress. Neurobiol Stress (2015) 0.81
Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis. Curr Neuropharmacol (2016) 0.81
Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome. J Gastroenterol (2015) 0.81
Production of corticotropin-releasing factor and urocortin from human monocyte-derived dendritic cells is stimulated by commensal bacteria in intestine. World J Gastroenterol (2014) 0.80
Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function. Gut (2002) 0.80
Role of anxiety in the pathophysiology of irritable bowel syndrome: importance of the amygdala. Front Neurosci (2009) 0.80
Facilitating return of bowel function after colorectal surgery: alvimopan and gum chewing. Clin Colon Rectal Surg (2013) 0.77
Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome. PLoS One (2016) 0.77
Distension-induced gastric contraction is attenuated in an experimental model of gastric restraint. Obes Surg (2010) 0.76
Control of irritable bowel syndrome with polyamine analogs: a structure-activity study. Dig Dis Sci (2001) 0.76
Methylnaltrexone in the treatment of opioid-induced constipation. Clin Exp Gastroenterol (2008) 0.75
Endogenous opioids: opposing stress with a cost. F1000Prime Rep (2015) 0.75
Experience of anger in patients with irritable bowel syndrome in Romania. Clujul Med (2014) 0.75
Correlations between anxiety and the stress responses of electrogastrography (EGG) induced by the mirror drawing test (MDT). J Smooth Muscle Res (2014) 0.75
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 7.47
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature (1983) 5.20
Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology (1983) 4.67
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A (2001) 3.23
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A (2001) 2.87
Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol (1993) 2.79
Diversity of Conus neuropeptides. Science (1990) 2.78
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 2.78
Peptide neurotoxins from fish-hunting cone snails. Science (1985) 2.77
Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature (1982) 2.44
Characterization of a bipartite activator domain in transcription factor CREB. Cell (1990) 2.41
Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature (1986) 2.29
Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril (1993) 2.09
CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl) (1991) 2.04
[Short guideline for the management of dyspepsia]. Dtsch Med Wochenschr (2004) 2.01
Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (1996) 1.91
Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science (1984) 1.87
Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res (1983) 1.86
Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 1.82
Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A (1981) 1.78
The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol (2000) 1.77
Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. Science (1983) 1.77
Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci (1985) 1.77
Somatostatin. Recent Prog Horm Res (1975) 1.67
Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology (1982) 1.58
Characterization of rat hypothalamic corticotropin-releasing factor. Proc Natl Acad Sci U S A (1983) 1.58
"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab (1982) 1.57
Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion (2004) 1.57
Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci (1982) 1.57
Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometry-decapeptide-Edman degradation). Proc Natl Acad Sci U S A (1972) 1.57
Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med (1981) 1.57
Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res (1983) 1.55
Assay of corticotropin releasing factor. Methods Enzymol (1983) 1.53
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) (1999) 1.46
[Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol (2011) 1.46
Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A (1995) 1.45
The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. J Clin Endocrinol Metab (1981) 1.42
Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease. Aliment Pharmacol Ther (2007) 1.42
CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut (2005) 1.41
Detection and purification of inhibin using antisera generated against synthetic peptide fragments. Methods Enzymol (1989) 1.38
Reversed-phase high-performance liquid chromatography: preparative purification of synthetic peptides. J Chromatogr (1984) 1.37
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther (2005) 1.36
Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med (1984) 1.35
Transmembrane topography of nicotinic acetylcholine receptor: immunochemical tests contradict theoretical predictions based on hydrophobicity profiles. Biochemistry (1986) 1.33
In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology (1982) 1.32
Conotoxins. J Biol Chem (1991) 1.28
Corticotropin releasing factor (CRF): immunoreactive neurones and fibers in rat hypothalamus. Regul Pept (1982) 1.27
Purification and partial characterization of inhibin from porcine follicular fluid. Biochem Biophys Res Commun (1985) 1.27
Characterization of a teleost gonadotropin-releasing hormone. Proc Natl Acad Sci U S A (1983) 1.26
A new family of Conus peptides targeted to the nicotinic acetylcholine receptor. J Biol Chem (1995) 1.24
D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule. Biochem Biophys Res Commun (1975) 1.24
Characterization of rat hypothalamic growth hormone-releasing factor. Nature (1983) 1.24
Biologic and immunologic activities and applications of somatostatin analogs. Metabolism (1978) 1.23
Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet (1983) 1.23
Conantokin-T. A gamma-carboxyglutamate containing peptide with N-methyl-d-aspartate antagonist activity. J Biol Chem (1990) 1.22
Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. Am J Physiol (1986) 1.22
Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor. Nature (1983) 1.20
Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J Pharmacol Exp Ther (1997) 1.19
Corticotropin-releasing factor (CRF): central effects on mean arterial pressure and heart rate in rats. Endocrinology (1982) 1.19
A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol (1983) 1.19
Location of antigenic determinants on primary sequences of subunits of nicotinic acetylcholine receptor by peptide mapping. Biochemistry (1986) 1.18
Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab (1981) 1.17
Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med (1981) 1.16
Bombesin:potent effects on thermoregulation in the rat. Science (1977) 1.16
Inhibin A-subunit cDNAs from porcine ovary and human placenta. Proc Natl Acad Sci U S A (1986) 1.16
Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature (1988) 1.15
Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol (1987) 1.15
Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther (2004) 1.15
Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol. J Clin Invest (1983) 1.14
Characterization of melanin-concentrating hormone from rat hypothalamus. Endocrinology (1989) 1.13
[Preliminary observations on the mechanism of action of somatostatin, a hypothalamic factor inhibiting the secretion of growth hormone]. C R Acad Sci Hebd Seances Acad Sci D (1972) 1.13
Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails. Science (1998) 1.12
Ligand requirements of the human corticotropin-releasing factor-binding protein. Endocrinology (1995) 1.11
Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science (1986) 1.11
Neurotensin binding to extraneural and neural receptors: comparison with biological activity and structure--activity relationships. Mol Pharmacol (1980) 1.10
Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta. Nature (1987) 1.10
Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. N Engl J Med (1983) 1.10
Diffuse lesions in the CNS revealed by MR imaging in a case of Whipple disease. AJNR Am J Neuroradiol (2001) 1.09
Abdominal surgery-induced delayed gastric emptying in rats: role of CRF and sensory neurons. Am J Physiol (1992) 1.09
Effects of synthetic ovine corticotropin-releasing factor, glucocorticoids, catecholamines, neurohypophysial peptides, and other substances on cultured corticotropic cells. Endocrinology (1983) 1.08
Anatomic and phylogenetic distribution of somatostatin. Metabolism (1976) 1.08
Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. N Engl J Med (1974) 1.08
Inhibition of adrenocorticotropic hormone secretion in the rat by immunoneutralization of corticotropin-releasing factor. Science (1982) 1.08
Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats. Neurogastroenterol Motil (2007) 1.08
Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis. Biopolymers (1996) 1.07
A noncompetitive peptide inhibitor of the nicotinic acetylcholine receptor from Conus purpurascens venom. Biochemistry (1997) 1.07
Conformational studies on somatostatin and analogues. Biochemistry (1977) 1.07
Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology (1989) 1.06
Vasopressor receptor antagonist prevents behavioural effects of vasopressin. Nature (1981) 1.06
Corticotropin-releasing factor receptors in rat forebrain: autoradiographic identification. Science (1984) 1.06
Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol (1997) 1.06
Corticotropin releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Res (1986) 1.05
Bombesin-like activity: radioimmunologic assessment in biological tissues. Life Sci (1978) 1.05
Corticotropin-releasing factor and the brain-gut motor response to stress. Can J Gastroenterol (1999) 1.05
Brain regulation of gastric secretion: influence of neuropeptides. Proc Natl Acad Sci U S A (1980) 1.04
Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther (1996) 1.04
Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature (1983) 1.04
Corticotropin-releasing factor: effects on the sympathetic nervous system and oxygen consumption. Life Sci (1982) 1.03